PRTA Prothena Biosciences Profit After Tax

Corporate emblem and logo of Prothena Corporation PLC (PRTA)

This daily price chart for Prothena Corporation (PRTA) reflects the price action of an asset valued at -0.04. The business focuses on developing antibodies for the therapy of degenerative brain processes. A lack of commercial sales creates high risks, the success of which depends on clinical trial results. The company's key strength is its expertise in eliminating protein abnormalities to combat Parkinson's and Alzheimer's diseases.

PRTA (Prothena Corp) Company Net Income history from 07/04/2022 to 10/30/2026

Financial and market metric breakdowns for Prothena Corp (PRTA)

- stock value and consensus price forecast:
Market Price Prothena Corporation plc|PRTA - Price Target Chart
- market capitalization data:
Market Valuation Prothena Biosciences|PRTA - Total Company Value
- issuer book value statistics:
Accounting Value of a Share Prothena|PRTA - Company Book Value|Market-to-Book Ratio prothena.com|PRTA - Cumulative Company Assets
- debt and liquidity details:
Aggregate Debt to Capital Prothena Corporation|PRTA - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Prothena Biosciences|PRTA - Company Aggregate Debts|Debts to Book Value Prothena Biosciences|PRTA - Company Long-Term Debt|Company Short-Term Indebtedness Prothena|Quick Ratio prothena.com
- net income and valuation multiples indicators:
PRTA - Net Income
Fundamental valuation:PRTA prothena.com
Flagship merchandise of Prothena Corp

Prothena Corporation (PRTA) focuses on scaling innovative treatments for ALS and Alzheimer's disease as part of a strategic update. This indicator determines the resilience of the long-term business trend through an analysis of daily operating profit. The company's financial profit dynamics allow for the identification of consolidation and growth phases regardless of trading volumes. This helps balance the risk of missed opportunities during portfolio rebalancing. The metric serves as the foundation for assessing the effectiveness of the new clinical cycle.

Main competitors

Company Net Income Biogen Idec (BIIB)|Company Net Income Neurocrine Biosciences|regencellbioscience.com - Profit After Tax|Company Net Income Axsome Therapeutics, Inc. (AXSM)|ACAD (ACADIA Pharma) - Final Profit|Company Net Income Xenon Pharmaceuticals Inc XENE|Viking Therapeutics Corp (VKTX) - Company Net Income|SUPN: Net Income|catalystpharma.com - Profit After Payment of Taxes|DNLI: Net Profit|Harmony Biosciences Inc - Final Profit|BHVN (Biohaven Pharmaceutical) - Net Profit|Company Net Income Amylyx Corp AMLX|Company Net Income Trevi Therapeutics (TRVI)|praxismedicines.com - Company Profit|Net Profit AVXL (Anavex Life Sciences Corp.)|Net Profit CeriBell Inc CBLL|ALEC: Net Income|Final Profit ANNX (Annexon Biosciences Inc.)|OMER: Net Profit|Net Income neurogene.com|Company Net Income AC Immune SA|Company Net Income Voyager Therapeutics Inc VYGR|Company Net Income Neumora Therapeutics Inc (NMRA)|SCLX (Scilex Holding Company, Inc.) - Final Profit|Company Net Income Tevogen Bio Holdings TVGN|ACOG (Alpha Cognition Inc) - Profit After Tax|CGTX - Company Net Income|Company Net Income Inhibikase Therapeutics Inc|Cassava (SAVA) - Company Net Income|Assertio - Final Profit|COYA (Coya Therapeutics Inc) - Net Profit|Net Profit VistaGen Therapeutics Inc|Net Income OVID (Ovid Therapeutics Inc.)|Profit After Payment of Taxes ABOS|Net Profit CRVO (CervoMed Inc)|Net Financial Result Alterity Therapeutics Ltd. (ATHE)|CLNN - Company Net Income|Company Net Income PepGen Inc.|Jupiter Neurosciences Inc (JUNS) - Company Net Income|Company Profit RLMD|Company Net Income Annovis Bio Corp|Grace Tx - Profit After Tax|Company Net Income Firefly Neuroscience, Inc (AIFF)|KLTO (anewmeds.com) - Final Profit|NeuroSense Therapeutics Ltd. - Net Income|Profit After Payment of Taxes RVPH (Reviva Pharmaceuticals Holdings Inc.)|MetaVia, Inc. - Net Profit|NRXS - Net Profit|heliusmedical.com (HSDT) - Company Net Income|Company Profit PASG|NEUP (Neuphoria Therapeutics, Inc.) - Net Profit|Company Net Income Minerva Neurosciences Inc NERV|Net Income ATHA (Athira)|Net Profit Addex (ADXN)|Company Net Income Alzamend Neuro ALZN|Final Profit CYCN|PTIX - Company Net Income|Company Net Income Pasithea Therapeutics|cortigent.com (CRGT) - Company Net Income|Profit After Tax ATXI (Avenue Therapeutics Inc)|Company Net Income Brainstorm Cell|CARA: Final Profit|Company Net Income Chromocell Therapeutics Corp. (CHRO)|ELYM - Company Net Income|Intra-Cellular Therapies, Inc. - Net Income|Profit After Payment of Taxes LBPH (Longboard)|Marinus Pharmaceuticals - Net Profit|Final Profit NKGN (nkgenbiotech.com)|NRBO: Net Profit|Company Net Income Sage Therapeutics Inc. (SAGE)|Company Net Income Neurotrope|Company Profit TRVN (Trevena Inc)|Net Profit VIGL|Net Profit Anew Medical Inc. (WENA)|Cerevel Therapeutics, Inc. - Net Income